Evidence map›Paper›PMID 26870350›Full record

ArticleMolecular and clinical oncology2016

Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients.

Xiufang Li, Ruixia Huang, Ruth Holm Li, Claes G Trope, Jahn M Nesland, Zhenhe Suo

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiufang LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 455000, P.R. China; Department of Gynaecology, Anyang Tumour Hospital, Anyang, Henan 455000, P.R. China.
Ruixia HuangDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.
Ruth Holm LiDepartment of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.
Claes G TropeDepartment of Gynaecology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway; Department of Gynaecology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0379 Oslo, Norway.
Jahn M NeslandDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.
Zhenhe SuoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 455000, P.R. China; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.
University of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing body of evidence indicates that aberrant activation of epithelial-to-mesenchymal transition (EMT) plays a key role in tumor cell invasion and metastasis. Zinc finger E-box-binding homeobox factor 1 (ZEB1), as a crucial mediator of EMT, contributes to the malignant progression of various epithelial tumors. To determine whether ZEB1 is involved in the progression of ovarian cancer, we immunohistochemically evaluated the expression of ZEB1 in 238 cases of epithelial ovarian cancer (EOC) and analyzed its associations with clinicopathological parameters. Positive expression of ZEB1 was observed in 32.8% (78/238) of EOCs and it was found to be significantly associated with advanced tumor stage (P=0.001). The survival analysis indicated that the expression of ZEB1 was associated with a poor 5-year progression-free survival (PFS) (P=0.021). A similar tendency was also observed between the expression of ZEB1 and 5-year overall survival, although it did not reach statistical significance (P=0.118). Moreover, the multivariate analysis demonstrated that ZEB1 expression was an independent risk factor for 5-year PFS in ovarian cancer. Taken together, our data provide evidence that ZEB1 may play a crucial role in promoting aggressive ovarian carcinoma progression. Therefore, ZEB1 may serve as an effectively predictive marker and a potential target for therapeutic intervention in EOC.

Indexed as

epithelial-to-mesenchymal transitionovarian cancersurvivalzinc finger E-box-binding homeobox 1

Identifiers

PMID26870350
PMCPMC4727064
OpenAlexW2135922106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.